For research use only
| Cat No. | ABC-TC500S |
| Product Type | Human Nerve Tumors Cell Lines |
| Cell Type | Epithelial |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Product Code | SF295; SF.295; SF 295 |
SF-295 glioblastoma cells, PTEN/TP53 mutants, hypertriploid, non-tumorigenic, used in chemo research and NCI-60 panel for GBM biology and therapy testing.
SF-295 is a human glioblastoma cell line derived from a left frontal lobe tumor of a 67-year-old Caucasian female patient. The cells exhibit glial-like morphology and are hyperploid (modal number 118, range 104-126) karyotype. SF-295 harbors homozygous mutations in key tumor suppressor genes PTEN and TP53, along with the TERT promoter C228T mutation frequently observed in glioblastoma multiforme (GBM). Additionally, SF-295 cells lack expression of typical glial markers GFAP and glutamine synthetase but express neurofibromin-1 (NF1). In vivo xenograft studies demonstrate that SF-295 cells are non-tumorigenic in nude mice. Widely used in preclinical research, SF-295 has been employed to evaluate chemotherapeutic agents such as temozolomide and BCNU, exhibiting tumor growth delay and synergistic effects in combination therapies. As a member of the NCI-60 panel, SF-295 serves as a valuable model for studying GBM biology and therapeutic response.
| Product Code | SF295; SF.295; SF 295 |
| Species | Human |
| Cat.No | ABC-TC500S |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Nerve Tumors Cell Lines |
The SF-295 cell line has broad utility in brain cancer research, particularly focused on glioblastoma multiforme (GBM), the most aggressive and malignant form of brain cancer. It serves as a standard brain tumor model in various cell line panel projects, making it invaluable in contemporary research. SF-295 is highly utilized in studies investigating chemotherapeutic treatments for glioblastoma, providing a valuable cellular model for assessing the impact of drugs and molecular modulators on glioblastomas. Through these applications, SF-295 contributes significantly to advancing our understanding and developing new treatment strategies for this devastating disease.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
